Guangzhou, January 15, 2021: New journal
BIO Integration (BIOI) publishes its fourth issue, volume 1, issue 4. BIOI is a peer-reviewed, open access, international journal, which is dedicated to spreading multidisciplinary views driving the advancement of modern medicine. Aimed at bridging the gap between the laboratory, clinic, and biotechnology industries, it will offer a cross-disciplinary platform devoted to communicating advances in the biomedical research field and offering insights into different areas of life science, in order to encourage cooperation and exchange among scientists, clinical researchers, and health care providers.
The issue contains an original article, three review articles, a mini review article and a commentary:
Announcing a new publication for
BIO Integration journal. In this review article the authors Zeling Guo, Shanping Jiang, Zilun Li and Sifan Chen from Sun Yat-Sen University, Guangzhou, China review how metabolic syndrome interacts with COVID-19.
Coronavirus disease 2019 (COVID-19) has rapidly spread worldwide and has exerted a great influence on public health and society. Metabolic disturbance involving various organs has been found in COVID-19 patients, including diabetes, fatty liver and acute kidney injury (AKI). In turn, pre-existing metabolic syndromes could exacerbate the effects of COVID-19. In this review, the authors focus on the close interaction between COVID-19 and metabolic syndrome, as well as the potential of repurposing metabolic-related drugs and the importance of treating metabolic diseases in COVID-19 patients.